Inventiva Shares Key Insights from 2024 Half-Year Report
Inventiva, a clinical-stage biopharmaceutical company, has recently filed its Half-Year Report covering the period up to June 30, 2024. The report is significant for investors and stakeholders, providing an overview of the company's financial status and strategic direction. Dedicated to addressing unmet medical needs, Inventiva focuses on innovative treatments for metabolic dysfunction and related health challenges.
Financial Overview
The preparation of the condensed consolidated interim financial statements was overseen by the Board of Directors and approved on a going concern basis. While the financial data presented in the report remained unqualified by statutory auditors, they noted a material uncertainty regarding the company's ongoing viability. This highlights the importance of Inventiva's forthcoming developments and the need for a robust strategy to ensure sustained growth.
Key Developments in the Pipeline
Inventiva is actively advancing its lead product candidate, lanifibranor, which is currently undergoing a pivotal Phase III clinical trial known as NATiV3. This trial is crucial for evaluating lanifibranor as a treatment option for patients suffering from metabolic dysfunction-associated steatohepatitis (MASH), a condition that poses significant health risks for affected individuals.
Exploring Further Opportunities
In addition to lanifibranor, the company is evaluating options for its preclinical programs, including odiparcil, a drug under consideration for MPS VI treatment. While efforts on this candidate have been temporarily suspended, Inventiva is diligently reviewing potential pathways for its future development. Simultaneously, the company is in the process of identifying new candidates focusing on the Hippo signaling pathway to expand its innovative treatment pipeline.
Company Expertise and Infrastructure
With a dedicated team of around 90 skilled professionals, Inventiva combines expertise in biology, medicinal chemistry, and clinical development, positioning itself as a formidable player in the biopharmaceutical landscape. The company boasts a rich library of pharmacologically relevant molecules, with approximately 240,000 compounds, showcasing its commitment to research and development.
Key Resources Available for Stakeholders
Investors and interested parties can access the 2024 Half-Year Report and Universal Registration Document directly from the company’s website. Furthermore, the report can be reviewed through investment platforms which are dedicated to ensuring transparency and enhanced accessibility for all stakeholders.
About Inventiva
As a public company listed on Euronext Paris and the Nasdaq Global Market, Inventiva is focused on developing its portfolio to cater to patients with MASH/NASH and other rare diseases urgently in need of effective therapies. Their expert team and extensive research facilities underscore their commitment to developing groundbreaking treatments that meet critical health demands.
Contact details for inquiries include:
Inventiva
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937
Frequently Asked Questions
What is the primary focus of Inventiva?
Inventiva is dedicated to developing oral small molecule therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) and other diseases.
What key product is Inventiva currently developing?
The lead product candidate is lanifibranor, which is in pivotal Phase III clinical trials designed to assess its efficacy for MASH patients.
Where can I find the Half-Year Report?
The Half-Year Report is available on Inventiva's website under the “Investors” section.
Is Inventiva still pursuing development for odiparcil?
While the clinical development of odiparcil is currently suspended, Inventiva is exploring potential future steps for this candidate.
How can I contact Inventiva for more information?
Contact can be made via email to media@inventivapharma.com or through their main contact number at +1 202 499 8937.
